A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma
—
Glioblastoma
BioLineRx is currently supporting investigator-initiated clinical trials and research collaborations for the treatment of glioblastoma and pancreatic cancer. We encourage interested patients to speak with their healthcare team for more information on eligibility criteria for our active clinical trials.
Investigator-initiated studies of motixafortide are currently enrolling patients in the following locations:
A Phase 2b Study with Combination Chemotherapy (Gemcitabine and Nab-Paclitaxel), Chemokine (C-X-C) Motif Receptor 4 Inhibitor (BL-8040), and Immune Checkpoint Blockade (Cemiplimab) in Metastatic Treatment-naïve Pancreas Adenocarcinoma
Pancreatic Cancer
BioLineRx’s commitment to patients in need is supported not only through our own clinical studies, but also by supporting independent, unsolicited research relating to motixafortide by external investigators, organizations, and institutions as part of our Investigator Initiated Studies (IIS) program. IIS proposals submitted to BioLineRx are reviewed by our scientific and medical committees for scientific merit as well as safety, legal, ethical, and budgetary considerations. Support by BioLineRx can take the form of funding, study drug, or a combination of both.
To submit a proposal or for any further information, please email info@biolinerx.com.
Learn about our growing pipeline of best-in-class therapeutics for patients with cancer and rare disease.
